Northern Ireland company Millicent Pharma is a leading specialty pharmaceutical business dedicated to advancing women’s health through innovation and scientific excellence. With a strong foundation built through strategic acquisitions of products, Millicent has evolved into a fully integrated organization with a range of branded women’s health therapies and a strong R&D pipeline.
Millicent continues to invest in its internal R&D operations, focusing on the development of novel therapeutics and enhanced dosage forms.
In addition to organic growth, the company actively pursues strategic opportunities to expand its portfolio through product in-licensing, acquisitions, and partnerships. These initiatives are carefully selected to align with Millicent’s mission and to further leverage the strengths of its commercial and scientific teams.
Ryan Loughlin serves as Millicent’s Senior Vice President, Head of Technical Operations and Quality. In this role, Dr Loughlin leads Millicent’s technical operations, which includes research & development, operational excellence, and product validations. He is also responsible for Millicent Quality, with quality oversight for R&D, clinical, manufacturing and distribution.
Dr Loughlin has 18 years of experience in R&D, operational excellence, manufacturing, and quality-related functions. He joined Millicent as Vice President, Head of Pharmaceutical Development & Pharmaceutical Technology and prior to this role, he held senior positions in Adapt Pharma, Allergan, and Warner Chilcott.
He earned his master’s degree in pharmacy and a PhD in pharmaceutics and Queen’s University of Belfast.
Dr Loughlin has a global role, with reports in multiple countries across Northern Ireland, Ireland, Germany and the USA and he is also the site head of Millicent’s manufacturing and R&D site in Larne.
“At the Larne site, we manufacture FDA approved pharmaceutical products, developing next generation therapeutics for the advancement of women’s health.
Millicent currently sells 3 different FDA approved Brands; Femring®, Intrarosa® and Femlyv®.
Femring is a long-acting treatment for the vasomotor/general symptoms of the menopause. Whilst Intrarosa treats local symptoms of the menopause.
“Femlyv, our most recent product launch, is a combined oral contraceptive. Millicent’s research and development team brings deep expertise across key disciplines—including pharmaceutical development, clinical operations, and regulatory affairs—to drive innovation and deliver high-quality, patient-focused solutions.
“With a focus on women’s health, Millicent has novel therapeutics in development for contraception and hormone replacement therapy. In addition, Millicent investigates therapeutic options for other women’s health conditions.”
